Background and Objectives Vaginal pixelated low power and long pulses (LPLP) CO2 laser has been suggested as an optional treatment for stress urinary incontinence (SUI) with many studies reporting short‐term improvements. The objective of this study was to assess the 1‐year subjective and objective efficacy of vaginal CO2 laser in women with urodynamic SUI. Study Design/Materials and Methods This was a prospective multicenter study. Patients with confirmed urodynamic SUI graded as mild or moderate were included. We used three sessions of fractional pixelated CO2 laser for vaginal application and followed up the patients at 6 and 12 months. We used the following measures at follow‐up: 1‐hour pad test (ICS protocol), questionnaires including Pelvic Floor Distress Inventory 20 (PFDI‐20), Pelvic Floor Impact Questionnaire (PFIQ), Patient Global Impression of Improvement (PGI‐I), and a 3‐day urinary diary. The urodynamic assessment was repeated at 6 months. Results Fifty‐two patients with SUI had three laser treatments, of whom 48 completed a 6‐month follow‐up and 42 patients completed 12‐month follow‐up. No serious adverse events were recorded during the study period. A significant reduction on the 1‐hour pad test was found from baseline (6.3 ± 1.6 g) to the 12‐month follow‐up (3.7 ± 1.4 g, P < 0.05) was found. PGI‐I showed 75.0%, 61.9%, and 64.3% improvements at 3, 6, and 12 months, respectively. PFDI improved significantly and consistently from baseline until 12 months (37.2 ± 3.89 to 16.1 ± 3.7, P < 0.05). Similarly, PFIQ showed significant improvements from the first treatment up to 12 months. Urodynamic assessment at 6 months showed that 41.4% of patients had no stress incontinence. Conclusion The vaginal CO2 laser was found to be effective for mild‐to‐moderate SUI over a follow‐up period of 1 year, according to a variety of objective and subjective parameters. The wide range of parameters enables optimal patient consultation and subsequent treatment. Lasers Surg. Med. © 2020 Wiley Periodicals LLC

Cautious selection and close monitoring of candidates are the cornerstones of successful management of TOLAC. Readily available facilities for emergency cesarean delivery and concerted obstetrical team can save the mother and child from catastrophic complications.

PCD in Israel is rare, with comprehensive diagnostic tests showing prevalence in children similar to Europe. Prevalence was higher in non-Jews, associated with parental consanguinity. Diagnostic and management practices vary. Referral centers providing comprehensive diagnostic and care capabilities should be established.

Local pathogens and their antibiotic sensitivity profiles should be explored every few years and an effective antibiotic protocol chosen to cover the main pathogens causing chorioamnionitis and EOS. Consideration should be made for changing ampicillin in women with PPROM to a regimen with better coverage of gram-negative Enterobacteriaceae.